Target type: biologicalprocess
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ozone stimulus. [GOC:sm]
Ozone is a powerful oxidant that can cause significant damage to living organisms. Upon exposure to ozone, cells initiate a complex series of responses aimed at mitigating its harmful effects. These responses involve a coordinated effort of multiple cellular pathways, including oxidative stress signaling, DNA repair mechanisms, and antioxidant defense systems.
Firstly, ozone can directly react with cellular components, including lipids, proteins, and DNA, leading to oxidative stress. This oxidative stress is characterized by an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense systems. Ozone-induced ROS can trigger various signaling pathways, including the activation of transcription factors like NF-κB and AP-1, which regulate the expression of genes involved in inflammation and immune responses.
Secondly, ozone can damage DNA, leading to the formation of DNA adducts and strand breaks. To repair these damages, cells activate DNA repair pathways, such as nucleotide excision repair and base excision repair, to restore the integrity of the genome. These repair pathways involve a series of enzymes that remove damaged nucleotides and replace them with the correct ones.
Thirdly, to combat the oxidative stress caused by ozone, cells activate antioxidant defense systems. These systems include enzymes like superoxide dismutase (SOD), catalase, and glutathione peroxidase, which neutralize ROS and prevent oxidative damage. In addition, cells can also produce antioxidants like glutathione and vitamins C and E, which can directly scavenge free radicals.
Overall, the response to ozone is a multifaceted process involving complex cellular signaling pathways, DNA repair mechanisms, and antioxidant defenses. These responses are essential for mitigating the damaging effects of ozone and maintaining cellular homeostasis.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Substance-P receptor | A substance-P receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25103] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| astemizole | astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects. | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
| clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
| econazole | 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. Econazole: An imidazole derivative that is commonly used as a topical antifungal agent. | dichlorobenzene; ether; imidazoles; monochlorobenzenes | |
| miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
| substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
| paroxetine | paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression. | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor |
| phenylalanylphenylalanylamide | |||
| cp 96345 | CP 96345: structure given in first source; potent nonpeptide antagonist of the substance P (NK1) receptor; CP 96344 is enantiomer of CP 96345 | ||
| sr 48968 | SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968 | ||
| 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one | 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one: structure given in first source; RP 68651 is the inactive (3aS,7aS)-isomer; substance P antagonist | ||
| senktide | |||
| (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine | (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine: structure given in first source | ||
| l 703606 | L 703606: structure given in first source | ||
| 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist | ||
| l 733060 | 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source | piperidines | |
| win 64821 | WIN 64821: a dimerized Trp-Phe condensate; structurally similar to verticillins and chaetocins; a nonpeptide neurokinin antagonist; structure given in first source; substance P antagonist | ||
| substance p, pro(9)- | substance P, Pro(9)-: RN given refers to the (L-Pro)-isomer; RN for cpd without isomeric designation not available 3/91 | ||
| substance p, sar(9)-met(o2)(11)- | substance P, Sar(9)-Met(O2)(11)-: a neurokinin-1 receptor agonist | ||
| ranatachykinin a | ranatachykinin A: a tachykinin in frog (Rana catesbeiana) brain and intestine | ||
| sr 142806 | |||
| tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
| cp 99994 | 3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer | ||
| neurokinin a | Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI. | ||
| neurokinin b | Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS. | polypeptide | |
| sb 223412 | SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source | ||
| seglitide | seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist | ||
| biphalin | biphalin: enkephalin dimer; two fragments of Ala(2)-enkephalin are connected by a diamine bridge to form above cpd; structure given in first source | ||
| netupitant | netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. netupitant: orally active neurokinin-1 receptor antagonist | aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes | antiemetic; neurokinin-1 receptor antagonist |
| sb 222200 | quinolines | ||
| sb 218795 | SB 218795: structure in first source | quinolines | |
| substance p (6-11), tyr(6)-d-phe(7)-d-his(9)- | substance P (6-11), Tyr(6)-D-Phe(7)-D-His(9)-: substance P antagonist | ||
| vofopitant | |||
| pd 154075 | PD 154075: a non-peptide tachykinin NK1 receptor antagonist; structure given in first source | ||
| edotecarin | |||
| (2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine | (2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine: structure given in first source | ||
| vestipitant | |||
| ly 306740 | LY 306740: LY-307679 is the inactive enantiomer | ||
| sdz nkt 343 | SDZ NKT 343: structure in first source | ||
| orvepitant | |||
| zd 6021 | ZD 6021: structure in first source | ||
| tak 637 | TAK 637: structure in first source | ||
| casopitant | piperidines | ||
| nkp 608 | |||
| dnk 333 | DNK 333: a dual neurokinin NK1/NK2 receptor antagonist; structure in first source | ||
| 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
| rolapitant | azaspiro compound; ether; organofluorine compound; piperidines; pyrrolidin-2-ones | antiemetic; neurokinin-1 receptor antagonist | |
| spiroquinazoline | spiroquinazoline: isolated from the fungus Aspergillus flavipes; structure given in first source; substance P antagonist | ||
| ditryptophenaline | ditryptophenaline: structure in first source | ||
| serlopitant | |||
| nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
| aprepitant | aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist |
| l 742694 | L 742694: a neurokinin-1 receptor antagonist; structure given in first source |